Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tele-monitoring.
- Who it may be relevant to
- Registry conditions: Melanoma, Lung Cancer, Renal Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The ipilimumab and nivolumab combination is now part of the standard of care for the treatment of melanoma, renal and lung cancer patients. Grade 3/4 adverse events (AEs) occur in 30 to 60% of patients included in clinical trials. Grade 3/4 AEs are more frequently observed (50-60% of patients) in melanoma because ipilimumab is administrated at 3mg/kg in this population. Among these AEs, early detection of immune related AEs is critical to an adequate medical management. In this context, dedicated tools for remote monitoring of these patients are crucial. The investigators developed within the Immucare consortium a simplified medical questionnaire which is addressed weekly to the patients. This questionnaire along with an algorithm gives to the clinician regular feedback on their patients' general symptoms. The investigators herein want to evaluate in a randomized prospective trial the efficacy of this remote monitoring to reduce the time between the start of AE and the reporting to the medical team, which could lead to detect and treat earlier AEs induced by nivolumab and ipilimumab in the melanoma, lung and renal cancer patients' population.
Interventions
- Behavioral Tele-monitoring
The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalizati
Primary outcome measures
- Delay between the start of a side effect and reporting to the medical team (average number of days per patient). [Time frame: 12 months]
Secondary outcome measures (9)
- Levels of morbidity based on CTC-AE v5 (all toxicities) [Time frame: 12 months]
- Number of treatment interruptions and number of days of treatment delays interruptions, number of treatment discontinuation, number of dose reductions and and percentage of dose reduction [Time frame: 12 months]
- Number of admissions in the emergency room [Time frame: 12 months]
- Number of unplanned hospitalizations [Time frame: 12 months]
- Number of contact with general practitioner [Time frame: 12 months]
- benefit for clinicians: interview of clinicians on their opinion on the self-monitoring, evaluation to the impact on the consultations during the first year of treatment, assessed with satisfaction questionnaires [Time frame: Month 12]
- Number of AE identified by clinicians [Time frame: 12 months]
- Overall quality of Life assessed with standardized QoL questionnaires (FACT-G) [Time frame: 12 months]
- Adherence: The number of full symptoms report completions and adherence to the completion schedule [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Age > 18 years
- Patients diagnosed with melanoma, or lung cancer or renal cancer
- Patients starting a treatment with a combination of immunotherapy of nivolumab + ipilimumab (NB: patients who have already received immunotherapy in the past may be included)
- Patients comfortable with the use of digital tools and computing
- Patients who agree to participate to the telemonitoring and signed consent form
Exclusion criteria
- Pregnant, parturient and lactating women
- Patients under legal protection measure or deprived of their liberty
- Patients not affiliated to a social security scheme (schemes such as the AME) or beneficiaries of a similar regime (foreign person, outside the EU)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
France · 10 centers
- Groupement hospitalier Est - Multidisciplinary oncological platform — Bron
- Hôpital Louis Pradel - Department of Pneumology — Bron
- University hospital of Grenoble Alpes - Department of dermatology — Grenoble
- University hospital of Grenoble Alpes - Department of Medical Oncology — Grenoble
- Hôpital de la Croix Rousse - Department of Pneumology — Lyon
- Hôpital Edouard Herriot - Department of urology — Lyon
- Centre Hospitalier Lyon Sud - Department of Medical Oncology — Pierre-Bénite
- Hôpital Lyon Sud - Department of Dermatology, HCL-Cancer Institute — Pierre-Bénite
- … and 2 more centers
Identifiers
NCT: NCT04605146 · 69HCL20_0492 · 2020-A02372-37